Thymosin alpha-1 (Tα1) is the most clinically validated immunomodulatory peptide, with decades of use in hepatitis B treatment and cancer immunotherapy adjunction. This protocol covers its application for general immune support, immune reconstitution, and specific clinical contexts.

Mechanism summary

Tα1 is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5). Its immunomodulatory effects include:

Enhancement of dendritic cell maturation and antigen presentation
Promotion of T-cell differentiation and maturation
Increased NK cell cytotoxicity
Increased regulatory T-cell (Treg) function
Restoration of Th1/Th2 balance

The key distinction: Tα1 is an immunomodulator, not an immunostimulant. It restores immune balance rather than non-specifically amplifying immune activity. This makes it theoretically appropriate for both immunodeficient and autoimmune-adjacent conditions — a claim supported by its safety record in immunocompromised populations.

Dose and route

Standard dose: 1.6 mg subcutaneous injection

Route: Subcutaneous, typically abdominal or deltoid

Volume: Typically 0.5–1.0 mL depending on concentration

This dose is consistent across virtually all clinical applications — it is the dose used in Zadaxin (the pharmaceutical form of Tα1 approved in multiple countries for hepatitis B).

Frequency schedules by context

General immune maintenance

1.6 mg subcutaneous, 2 times per week (e.g., Monday and Thursday)

Duration: 8–12 week cycles, 2–3 cycles per year

Best for: Adults over 40 seeking immune optimization, seasonal immune support, individuals with mild-moderate immune concerns

Acute immune challenge

1.6 mg subcutaneous daily for 7–14 days, then transition to 2–3 times weekly

Duration: Daily phase + 4–8 weeks maintenance

Best for: Active infection support, post-illness immune recovery, perioperative immune support (before/after surgery)

Immune reconstitution (post-illness, chronic fatigue, long COVID)

1.6 mg subcutaneous, 3 times per week for 4 weeks, then 2 times per week for 8 additional weeks

Duration: 12 weeks total

Best for: Post-viral immune dysregulation, chronic fatigue with documented immune markers, T-cell exhaustion

Maintenance after initial course

1.6 mg subcutaneous, 1–2 times per week ongoing or in 8-week cycles

Best for: Long-term immune optimization in individuals with documented benefit from initial course

Immune monitoring

Baseline panel (before starting)

Complete blood count with differential
Lymphocyte subset panel: CD4, CD8, CD4/CD8 ratio, NK cells (CD56+)
Immunoglobulins: IgG, IgA, IgM
CRP, ESR (inflammatory markers)
Optional: T-cell proliferation assay, NK cell functional assay

Follow-up (4 weeks and 12 weeks)

Repeat lymphocyte subsets — look for improved CD4/CD8 ratio, increased NK cell count
Repeat inflammatory markers — look for reduced CRP/ESR
Clinical assessment: infection frequency, energy levels, symptom tracking

What to look for:

CD4/CD8 ratio normalizing toward 1.5–2.5
NK cell count increasing
Reduced frequency of infections
Improved energy and exercise tolerance

Combination strategies

Tα1 + KPV (immune modulation + anti-inflammatory)

For conditions with both immune dysregulation and active inflammation (post-viral syndromes, chronic GI inflammation):

Tα1 1.6 mg SC 2–3×/week
KPV 250 mcg SC daily or oral (for GI-targeted)
Duration: 8–12 weeks

Tα1 + LL-37 (immune modulation + antimicrobial)

For chronic infections with biofilm component (MARCoNS, chronic Lyme):

Tα1 1.6 mg SC 2–3×/week (immune reconstitution)
LL-37 100 mcg SC daily (antimicrobial + biofilm disruption)
Duration: 4–8 weeks

Tα1 + Vitamin D + Zinc (immune fundamentals)

For general immune optimization with nutritional support:

Tα1 1.6 mg SC 2×/week
Vitamin D3 5,000 IU daily (target 25-OH-D: 50–70 ng/mL)
Zinc 30–50 mg daily (with copper 2 mg to prevent imbalance)

Safety considerations

Tα1 has an excellent safety profile based on decades of clinical use:

No significant adverse effects in clinical trials across hepatitis B, cancer adjunction, and immunodeficiency applications
Injection site reactions (mild redness, soreness) are the most common side effect
No immunosuppressive effects — Tα1 does not increase infection risk
Safe in combination with vaccines (may enhance vaccine response)

Cautions:

Organ transplant recipients on immunosuppression — Tα1 could theoretically interfere with immunosuppressive regimens. Do not use without transplant specialist supervision
Active autoimmune flares — while Tα1's mechanism includes Treg promotion (which should help autoimmunity), starting during an active flare introduces unpredictability. Start during quiescent periods
Concurrent immunotherapy (checkpoint inhibitors) — Tα1 has been used as an adjunct, but the interaction with modern immunotherapy agents (anti-PD-1, anti-CTLA-4) should be managed by an oncologist